K. ZHENG ET AL.Gold-nanoparticle-based multistage drug delivery system for antitumor therapy

Drug Deliv. 2022 Dec;29(1):3186-3196. doi: 10.1080/10717544.2022.2128469.

Abstract

Nanoparticles can promote the accumulation of drugs in tumors. However, they find limited clinical applications because they cannot easily penetrate the stroma of cancer tissues, and it is difficult to control drug release. We developed a multiresponse multistage drug-delivery nanogel with improved tumor permeability and responsiveness to the tumor microenvironment for the controlled delivery of anticancer agents. For this purpose, ∼100 nm multistage drug delivery nanogels with pH, redox, near-infrared stimulation, and enzyme responsiveness were grown in situ using 20 nm gold nanoparticles (AuNPs) via an emulsion-aiding crosslinking technique with cysteine crosslinker. An alginate cysteine AuNP (ACA) nanocarrier can efficiently load the cationic drug doxorubicin (DOX) to produce a multistage drug delivery nanocarrier (DOX@ACA). DOX@ACA can maintain the slow release of DOX and reduce its toxicity. In cancer tissues, the high pH and reductase microenvironment combined with the in vitro delivery of alginate and near-infrared light drove drug release. The developed nanoparticles effectively inhibited cancer cells, and in vivo evaluations showed that they effectively enhanced antitumor activity while having negligible in vivo toxicity to major organs.

Keywords: Alginate; antitumor therapy; gold nanoparticle; multistage drug delivery; nanogel; pH/redox/enzyme responsiveness.

MeSH terms

  • Alginates
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cysteine
  • Doxorubicin
  • Drug Carriers
  • Drug Delivery Systems
  • Drug Liberation
  • Emulsions
  • Gold
  • Hydrogen-Ion Concentration
  • Metal Nanoparticles*
  • Nanogels
  • Nanoparticle Drug Delivery System
  • Nanoparticles*
  • Oxidoreductases

Substances

  • Alginates
  • Antineoplastic Agents
  • Drug Carriers
  • Emulsions
  • Nanogels
  • Nanoparticle Drug Delivery System
  • Gold
  • Doxorubicin
  • Oxidoreductases
  • Cysteine

Grants and funding

The research was supported by the National Key R&D Program of China (2018YFE0201500 and 2017YFB0309300), the National Natural Science Foundation of China (81772317, 51973060, 82072051 and 81771964), the National Natural Science Foundation of China for Innovative Research Groups (51621002) and the funding grant from Shanghai International Cooperation Program (15520721200). This study was financially supported by grants from the special project of clinical research of the health industry of Shanghai Municipal Health Commission (Nos. 201940178), the scientific research project of Hongkou District Health Committee of Shanghai (Nos. 2002-17) and the research project of Shanghai Fourth People’s Hospital (sykyqd 701 and 702).